Anaplastic Ependymoma, WHO Grade III

Comprehensive Clinical Guide: Anaplastic Ependymoma (WHO Grade III)

1. Introduction and Clinical Overview

Anaplastic Ependymoma, classified by the World Health Organization (WHO) as a Grade III central nervous system (CNS) neoplasm, represents a highly aggressive, malignant variant of ependymoma. Ependymomas arise from ependymal cells—the glial cells that line the ventricular system of the brain and the central canal of the spinal cord. While classic ependymomas (WHO Grade II) are characterized by slow growth and better prognosis, Anaplastic Ependymoma is distinguished by its rapid cellular proliferation, increased mitotic activity, and tendency for local recurrence and dissemination.

Clinically, this condition is a significant challenge in neuro-oncology. Because these tumors frequently arise in the posterior fossa (particularly in pediatric populations) or the supratentorial regions, they often exert mass effect on critical brain structures, leading to hydrocephalus, intracranial hypertension, and focal neurological deficits. The management of WHO Grade III Ependymoma requires a multidisciplinary approach involving neurosurgery, radiation oncology, and neuro-oncology.

2. Etiology and Pathophysiology

The precise trigger for the oncogenesis of Anaplastic Ependymoma remains a subject of intense investigation. Unlike some other gliomas, ependymomas exhibit distinct molecular signatures based on their anatomical location.

Pathophysiological Mechanisms:

• Cellular Origin: These tumors originate from radial glial cells that act as neural stem cells in the subventricular zone.
• Molecular Drivers: A hallmark of many posterior fossa ependymomas is the C11orf95-RELA fusion, which triggers constitutive activation of the NF-κB signaling pathway. This pathway is critical for cell survival, proliferation, and anti-apoptotic signaling.
• Genetic Instability: Grade III tumors exhibit high rates of chromosomal instability, including losses on chromosome 6q, 9p (CDKN2A locus), and 13q.
• Histological Markers: Under microscopic examination, these tumors display high cellularity, brisk mitotic activity, microvascular proliferation, and frequent areas of necrosis (pseudopalisading necrosis), which is a key differentiator from Grade II lesions.

3. Clinical Presentation and Staging

The clinical presentation of Anaplastic Ependymoma is largely determined by the tumor's location and its impact on cerebrospinal fluid (CSF) flow.

Standard Presentation Symptoms:

• Intracranial Pressure (ICP) Elevation: Morning headaches, projectile vomiting, papilledema, and lethargy.
• Posterior Fossa Syndrome: Ataxia, cranial nerve palsies, dysmetria, and nystagmus.
• Supratentorial Signs: Focal motor weakness, seizures, and personality changes.
• Spinal Symptoms (if applicable): Localized pain, radiculopathy, and bowel/bladder dysfunction.

Staging and Grading:

Unlike systemic cancers that utilize TNM staging, CNS tumors utilize the WHO Classification of Tumors of the Central Nervous System. Staging for ependymoma primarily involves:
1. Extent of Resection (EOR): Gross Total Resection (GTR) vs. Subtotal Resection (STR).
2. Dissemination Status: Evaluation via MRI of the entire neuraxis (brain and spine) to rule out leptomeningeal spread (M-staging).

4. Key Diagnostic Tests

A definitive diagnosis of Anaplastic Ependymoma requires a combination of neuroimaging and histopathological confirmation.

• Magnetic Resonance Imaging (MRI): The gold standard. T1-weighted imaging with contrast usually shows heterogeneous enhancement. T2/FLAIR sequences are used to assess peritumoral edema.
• Magnetic Resonance Spectroscopy (MRS): Often reveals elevated choline and reduced N-acetylaspartate (NAA) peaks, typical of high-grade metabolic activity.
• CSF Cytology: Performed via lumbar puncture (if ICP is not elevated) to detect malignant cells in the subarachnoid space.
• Histopathology & IHC: Immunohistochemistry testing for GFAP (positive), EMA (dot-like cytoplasmic staining), and Ki-67 labeling index (typically elevated in Grade III).

5. Standard Treatment Protocols

Treatment is aggressive and multimodal due to the high risk of recurrence.

1. Neurosurgical Resection: The primary goal is GTR. Survival outcomes are statistically superior when no residual tumor is visible on post-operative MRI within 48–72 hours.
2. Adjuvant Radiation Therapy (RT): Standard of care for WHO Grade III tumors. Focal, high-dose conformal radiation is typically delivered to the surgical bed.
3. Chemotherapy: While its role is less defined than in other brain tumors, chemotherapy (e.g., cisplatin, etoposide, or cyclophosphamide) is often utilized in pediatric cases or in instances of recurrent/progressive disease where RT options are exhausted.

6. Risks, Side Effects, and Contraindications

The treatment of Anaplastic Ependymoma carries significant risks due to the sensitive nature of the central nervous system.

• Surgical Risks: Damage to the brainstem, cranial nerve injury, post-operative hemorrhage, and CSF leak.
• Radiation Side Effects:
  • Acute: Fatigue, scalp erythema, nausea.
  • Chronic: Cognitive decline, endocrine dysfunction (hypopituitarism), radiation necrosis, and secondary malignancy risk.
• Contraindications: There are few absolute contraindications to treatment, though a patient’s performance status (Karnofsky Score) must be evaluated to determine if they can withstand the rigors of aggressive resection and adjuvant therapy.

7. Long-Term Prognosis

Prognosis for Anaplastic Ependymoma is guarded. While modern neuro-oncology has improved survival rates, the risk of recurrence remains high.

• Survival Rates: 5-year overall survival (OS) varies significantly based on age, tumor location, and success of GTR.
• Recurrence: Most recurrences occur locally at the original tumor site. Surveillance involves serial MRI scans every 3–6 months for the first several years post-treatment.
• Quality of Life (QoL): Long-term survivors often face neurocognitive deficits, requiring physical, occupational, and speech therapy.

8. Frequently Asked Questions (FAQ)

1. Is Anaplastic Ependymoma curable?
"Cure" is a difficult term in neuro-oncology. While many patients achieve long-term remission, the aggressive nature of Grade III tumors means they are prone to recurrence. Treatment is focused on maximizing progression-free survival.

2. Why is surgery considered the most important factor?
The extent of resection (EOR) is the strongest prognostic factor. Residual tumor cells act as a nidus for recurrence, which is why GTR is the primary goal of neurosurgeons.

3. Does the location of the tumor change the prognosis?
Yes. Posterior fossa ependymomas, particularly those in infants, often have a more complex biology and potentially poorer outcomes compared to spinal ependymomas.

4. What is the role of molecular testing?
Molecular testing (e.g., assessing for RELA fusion) is becoming standard practice to help predict tumor behavior and potentially identify candidates for targeted molecular therapies in the future.

5. How often is follow-up imaging required?
Typically, patients undergo MRI scans every 3 months for the first 2 years, followed by 6-month intervals, and eventually annual scans if the patient remains stable.

6. Are there specific clinical trials for this condition?
Yes, clinical trials are ongoing, investigating novel agents such as PARP inhibitors, immunotherapy, and personalized vaccine therapies for high-grade gliomas.

7. Can Anaplastic Ependymoma spread to other parts of the body?
Extraneural metastasis is extremely rare. The primary concern is spread within the central nervous system via the CSF pathways (leptomeningeal dissemination).

8. What is the difference between Grade II and Grade III ependymoma?
Grade III (Anaplastic) shows significantly higher cell division, more disorganized tissue architecture, and faster clinical progression compared to Grade II.

9. How do we manage hydrocephalus associated with these tumors?
Hydrocephalus is managed via surgical decompression of the tumor or, if persistent, the placement of a ventriculoperitoneal (VP) shunt.

10. What support systems are available for patients?
Multidisciplinary support, including neuro-oncology social workers, physical therapists, and support groups, is essential for managing the long-term cognitive and physical impacts of the disease.

9. Conclusion

Anaplastic Ependymoma, WHO Grade III, remains one of the most complex diagnoses in neuro-oncology. The transition from diagnosis to survivorship is a marathon that requires precision medicine, surgical excellence, and compassionate care. As our understanding of the molecular landscape of these tumors deepens, we move closer to more targeted, less toxic therapies that will hopefully improve both the survival statistics and the quality of life for those affected by this challenging malignancy.

Disclaimer: This guide is for educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a board-certified neurosurgeon or oncologist regarding any medical condition.